Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

https://www.thelancet.com/collections/oncology?dgcid=hubspot_email_infocusalerts-oncology_feature&parent=001611&startPage=&ContentItemType=fla&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-9k2QUpm6mm2gmjLSZDFSWnDKCxJBlgPgEDHdyTzXrmKt71Y7Z2OuzvBYmss8wmQp3EcvxKkTROutA1biaZCxMBKALpWA&_hsmi=319552803&utm_content=319101856&utm_source=hs_email